Drugs / Somatostatin
Somatostatin
also known as
COLIRIOBCN070660 · Somatex · Somatosan · somatostatin-14 · Somatostatina · Somatostatine · SRIF-14
Trials 21
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06416969 | Jan 2024 → Jan 2028 expected | obesity disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT02631616 | Feb 2016 → Feb 2017 | prostate neoplasm | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 1 | NCT02026973 | Mar 2014 → Nov 2015 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01290172 | Dec 2010 → Dec 2013 | liver disorder | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00786825 | Dec 2004 → Dec 2017 | type 1 diabetes mellitus | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT00152399 | Sep 2000 → Oct 2005 | peptic ulcer disease | UCB Pharma | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01726075 | Feb 2013 → Nov 2015 | diabetic retinopathy | BCN Peptides | Completed | No outcome recorded |
| Phase 35 trials · 2 missed | ||||||
| Phase 3 | NCT02799212 | Jan 2018 → Apr 2024 | hepatocellular carcinoma | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 3 | NCT03000946 | May 2017 → Feb 2021 | pancreas disorder | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 3 | NCT02882347 | Jul 2015 → Jul 2017 | liver failure | Korea University Anam Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01053390 | Oct 2009 → Dec 2013 | gallbladder carcinoma | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT01060826 | May 2009 → May 2012 | acute pancreatitis | Sant Pau Research Institute | Unknown | Missed primary |
| Phase 43 trials · 1 met primary | ||||||
| Phase 4 | NCT03349424 | Jun 2018 → May 2019 | pancreas disorder | Peking Union Medical College Hospital | Completed | Met primary |
| Phase 4 | NCT01914692 | Jan → Jul 2013 | — | First Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 4 | NCT01082627 | Jun 2009 → Nov 2010 | intestinal obstruction | Nanjing PLA General Hospital | Completed | No outcome recorded |
| Phase not applicable6 trials · 1 missed | ||||||
| — | NCT07605611 | Nov 2025 → Jul 2027 expected | rectal cancer | Tongji Hospital | Recruiting | No outcome recorded |
| — | NCT02836353 | Jan 2017 → Mar 2019 | dumping syndrome, esophageal disorder, hypoglycemia | Cambridge University Hospitals NHS Foundation Trust | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01431781 | Aug 2011 → Dec 2012 | acute pancreatitis | Changhai Hospital | Unknown | No outcome recorded |
| — | NCT01426087 | Jul 2011 → Oct 2012 | esophageal varices | Yunsheng Yang | Unknown | No outcome recorded |
| — | NCT01062529 | Oct 2009 → Feb 2010 | acromegaly, diabetes mellitus, pituitary deficiency | University of Aarhus | Completed | No outcome recorded |
| — | NCT01267669 | Nov 2005 → Nov 2009 | cirrhosis of liver, esophageal varices with bleeding, portal hypertension | Govind Ballabh Pant Hospital | Completed | Missed primary |
| Comparator or background therapy17 trials | ||||||
| Phase 1 | NCT03241706 Comparator | Aug 2018 → May 2028 expected | hypoglycemia | Jason Winnick | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02748369 Comparator | Jul 2016 → Mar 2017 | hypermetabolism due to uncoupled mitochondrial oxidative phosphorylation 2 | K. Sreekumaran Nair | Completed | No outcome recorded |
| Phase 1 | NCT01665638 Background | Sep → Oct 2012 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 3 | NCT04010669 Comparator | Aug 2019 → Mar 2020 | portal hypertension | Laiko General Hospital, Athens | Unknown | No outcome recorded |
| Phase 4 | NCT03998293 Background | Nov 2022 → Dec 2023 | — | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 4 | NCT03998709 Background | Feb 2020 → Dec 2021 | — | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 4 | NCT04107428 Comparator | Dec 2019 → Aug 2020 | liver failure, portal hypertension | King Faisal Specialist Hospital & Research Center | Unknown | No outcome recorded |
| Phase 4 | NCT04358016 Comparator | Jan 2018 → Jan 2020 | cirrhosis of liver | Changhai Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01992198 Background | Jul 2012 → Dec 2015 | acute necrotizing pancreatitis | Erzhen Chen | Unknown | No outcome recorded |
| Phase 4 | NCT02757703 Comparator | May 2010 → Jan 2015 | esophageal varices with bleeding | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| Phase 4 | NCT01112852 Comparator | Dec 2006 → Apr 2010 | esophageal varices, hemorrhagic disease | National Science and Technology Council, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT00966355 Comparator | Sep 2006 → May 2010 | esophageal varices with bleeding | Korea University | Completed | No outcome recorded |
| — | NCT07304466 Comparator | Dec 2025 → Mar 2027 expected | portal hypertension | Istanbul Medipol University Hospital | Recruiting | No outcome recorded |
| — | NCT07252401 Comparator | Dec 2025 → Mar 2028 expected | cirrhosis of liver | General Hospital of Shenyang Military Region | Not yet recruiting | No outcome recorded |
| — | NCT07366710 Background | Nov 2024 → Oct 2027 expected | NAFLD1, glucose metabolism disease | Rigshospitalet, Denmark | Active not recruiting | No outcome recorded |
| — | NCT01321060 Comparator | Jan 2011 → Dec 2012 | acute pancreatitis | Nanjing University School of Medicine | Unknown | No outcome recorded |
| — | NCT00431665 Background | Jul 1999 → Jun 2000 | — | Medical University of Vienna | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 40 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Somatostatin | “A total of 908 patients with normal amylase levels who were undergoing ERCP were randomized to receive somatostatin 250 μg bolus injection before ERCP and 250 μg/hour...” PMID 25590178 ↗ Jan 201537“Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study.” PMID 38662619 ↗ Apr 2024 “Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation” NCT01321060 ↗ “COLIRIOBCN070660 Somatostatin 1mg/mL Eye drops, solution.” NCT01726075 ↗ |
| Known as | COLIRIOBCN070660 | “COLIRIOBCN070660 Somatostatin 1mg/mL Eye drops, solution.” NCT01726075 ↗ |
| Known as | Somatex | “somatostatin (Somatex®) will be administered as a 250 mcg bolus over 2 minutes, followed by a continuous infusion at 2.5 mcg/kg/hour.” NCT07304466 ↗ |
| Known as | Somatosan | “Somatostatin (Somatosan, BAG Health Care GmbH, Lich, Germany) was given by intravenous bolus (250 μg) followed by 250 μg/hour and continued for 3 days in group S.” NCT02757703 ↗ |
| Known as | somatostatin-14 | “Consequently, continuous intravenous infusion of somatostatin-14, the natural peptide hormone, associated with 10 to 50 time stronger affinity with all somatostatin receptor,...” NCT03000946 ↗ |
| Known as | Somatostatina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1823872 ↗ |
| Known as | Somatostatine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1823872 ↗ |
| Known as | SRIF-14 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1823872 ↗ |
| Action | Inhibit | “Somatostatin may be used to suppress endogenous insulin secretion” NCT00786825 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Somatostatin is a kind of traditional medicines” NCT01914692 ↗ |
| Route | Intravenous | “12 Mg/24 H IV Infusion” NCT00152399 ↗ |